We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > GLR2007

News List

Gan & Lee receives EMA orphan drug designation for Phase I drug candidate GLR2007 for the treatment of glioma prnasia
April 07, 2021
announced that the European Medicine Gan & Lee Pharmaceuticals Co., Ltd. Agency (EMA) Committee for Orphan Medicinal Products granted orphan drug designation for the investigational compound GLR2007, for the treatment of glioma.
Drug Candidate GLR2007 Granted FDA Orphan Drug Designation americanpharmaceuticalreview
September 18, 2020
Gan & Lee Pharmaceuticals announced the U.S Food and Drug Administration (FDA) has granted Orphan Drug Designation for GLR2007, for the treatment of malignant glioma. GLR2007 is a cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor that ...